Merck
  • Home
  • Search Results
  • Novel epigenetic target therapy for prostate cancer: a preclinical study.

Novel epigenetic target therapy for prostate cancer: a preclinical study.

PloS one (2014-05-24)
Ilaria Naldi, Monia Taranta, Lisa Gherardini, Gualtiero Pelosi, Federica Viglione, Settimio Grimaldi, Luca Pani, Caterina Cinti
ABSTRACT

Epigenetic events are critical contributors to the pathogenesis of cancer, and targeting epigenetic mechanisms represents a novel strategy in anticancer therapy. Classic demethylating agents, such as 5-Aza-2'-deoxycytidine (Decitabine), hold the potential for reprograming somatic cancer cells demonstrating high therapeutic efficacy in haematological malignancies. On the other hand, epigenetic treatment of solid tumours often gives rise to undesired cytotoxic side effects. Appropriate delivery systems able to enrich Decitabine at the site of action and improve its bioavailability would reduce the incidence of toxicity on healthy tissues. In this work we provide preclinical evidences of a safe, versatile and efficient targeted epigenetic therapy to treat hormone sensitive (LNCap) and hormone refractory (DU145) prostate cancers. A novel Decitabine formulation, based on the use of engineered erythrocyte (Erythro-Magneto-Hemagglutinin Virosomes, EMHVs) drug delivery system (DDS) carrying this drug, has been refined. Inside the EMHVs, the drug was shielded from the environment and phosphorylated in its active form. The novel magnetic EMHV DDS, endowed with fusogenic protein, improved the stability of the carried drug and exhibited a high efficiency in confining its delivery at the site of action in vivo by applying an external static magnetic field. Here we show that Decitabine loaded into EMHVs induces a significant tumour mass reduction in prostate cancer xenograft models at a concentration, which is seven hundred times lower than the therapeutic dose, suggesting an improved pharmacokinetics/pharmacodynamics of drug. These results are relevant for and discussed in light of developing personalised autologous therapies and innovative clinical approach for the treatment of solid tumours.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
アセトニトリル, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
メタノール, suitable for HPLC, ≥99.9%
Sigma-Aldrich
アセトニトリル, anhydrous, 99.8%
Sigma-Aldrich
メタノール, anhydrous, 99.8%
Sigma-Aldrich
塩化ナトリウム, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
メタノール, ACS reagent, ≥99.8%
Sigma-Aldrich
リン酸カリウム 一塩基性, ACS reagent, ≥99.0%
Supelco
酢酸アンモニウム, LiChropur, eluent additive for LC-MS
Sigma-Aldrich
塩化ナトリウム, for molecular biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
メタノール, HPLC Plus, ≥99.9%
Sigma-Aldrich
メタノール, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
リン酸カリウム 一塩基性, powder, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
塩化ナトリウム 溶液, 5 M in H2O, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
塩化ナトリウム, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
塩化ナトリウム 溶液, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
L-グルタミン, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
リン酸カリウム 一塩基性, ReagentPlus®
Sigma-Aldrich
アセトニトリル, for HPLC, for UV, ≥99.9% (GC)
Sigma-Aldrich
塩化ナトリウム 溶液, 5 M
Sigma-Aldrich
酢酸アンモニウム, for molecular biology, ≥98%
Sigma-Aldrich
アセトニトリル, ACS reagent, ≥99.5%
Sigma-Aldrich
酢酸アンモニウム, reagent grade, ≥98%
Sigma-Aldrich
アセトニトリル, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
メタノール, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
ヘキシルアミン, 99%
Sigma-Aldrich
L-グルタミン, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
酢酸アンモニウム, ACS reagent, ≥97%
SAFC
L-グルタミン
Sigma-Aldrich
塩化ナトリウム, meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%
Sigma-Aldrich
酢酸アンモニウム, ≥99.99% trace metals basis